Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

Inclusion Criteria: * Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer * Stage IIIB/IV * No prior chemotherapy * Presence of two-dimensional measurable disease. The measurable disease should not have been irradiated. * Absence or irradiated and stable central nervous system metastatic disease * Life expectancy of more than 3 months * Age ≥ 70 years. * Performance status (WHO) \< 3 * Patients "non-frail" according to comprehensive geriatric assessment * Adequate bone marrow function (Absolute neutrophil count \> 1000/mm\^3, Platelet count \> 100000/mm\^3, Hemoglobin \> 9gr/mm\^3). * Adequate liver (Bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl). * Adequate cardiac function (LVEF \> 50%). * Informed consent. Exclusion Criteria: * Psychiatric illness or social situation that would preclude study compliance. * Other concurrent uncontrolled illness. * Other invasive malignancy within the past 5 years except nonmelanoma skin cancer. * No presence of a reliable care giver * Other concurrent investigational agents.